ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
SPRY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ARS Pharmaceuticals, Inc.NASDAQ: SPRY
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $60.62M (cash outflow) rose 78.6% year over year, behind the +1165.0% change in trailing-twelve-month net income. Sequentially, it rose 46.7% from the prior quarter. Over 3 fiscal years it compounded at +70.3% a year.
Context
- Net income amounted to 203.3% of revenue in FY2025, up 194.3 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$178.88M (+4.4%) for the fiscal year ending Dec 2026, a step up from the -2241.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$60.62M+46.7% QoQ
- Last fiscal yearDec 2025
- -$171.3M-2241.8% YoY
- LTMMar 2026
- -$197.98M+1165.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +78.6% | +6.1% | -72.5 pp |
| 1 year | -2241.8% | +4.4% | +2246.2 pp |
| 3-year CAGR | +70.3% | -46.1% | -116.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (171.3M) USD
- Year-over-year change
- -2241.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (171.3M) | -2241.8% |
| FY2024 | 2024-12-31 | 8M | +114.7% |
| FY2023 | 2023-12-31 | (54.37M) | -56.8% |
| FY2022 | 2022-12-31 | (34.68M) | -71.3% |
| FY2021 | 2021-12-31 | (20.24M) | — |
Net Income vs competitors
How SPRY compares with its peers on the latest reported figures
- SPRY's LTM Mar 2026 net income of $197.98M is the largest of the 4 companies compared; the peer median is $23.91M.
- Its year-over-year change of +1165.0% is the highest of 4, against a peer median of +27.1%.
- Net income amounts to 200.0% of revenue for SPRY, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $197.98M | +1165.0% | +70.3% | 200.0% |
| LTM Mar 2026 | $68.91M | +27.1% | +15.5% | 137.1% | |
| LTM Mar 2026 | $23.91M | -179.4% | — | 6.6% | |
| LTM Mar 2026 | $12.01M | +126.6% | — | 3.8% | |
| Peer median (excluding SPRY) | $23.91M | +27.1% | +15.5% | 6.6% | |
Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.24M) | (34.68M) | (54.37M) | 8M | (171.3M) |
| Depreciation & Amortization | 213K | 319K | 73K | (7.18M) | 1.37M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.83M | 5.84M | 9.24M | 14.53M | 22.1M |
| Change in Working Capital | (356K) | (12.75M) | (7.33M) | (1.81M) | (20M) |
| Accounts Receivables | 0 | 0 | 0 | (8.18M) | (17.21M) |
| Inventory | 0 | 0 | 0 | (5.95M) | (21.99M) |
| Accounts Payables | 0 | (10.29M) | (2.78M) | 16.43M | 18.88M |
| Other Working Capital | (356K) | (2.47M) | (4.55M) | (4.12M) | 306K |
| Other Non-Cash Items | (4K) | 1.2M | (6.88M) | 0 | (3.03M) |
| Operating Cash Flow | (17.56M) | (40.08M) | (59.27M) | 13.55M | (170.87M) |
| Capital Expenditures | (55K) | (199K) | (175K) | (563K) | (339K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (272.01M) | (356.04M) | (242.03M) |
| Sales of Investments | 0 | 0 | 185M | 258M | 307M |
| Other Investing Activities | 0 | 0 | 0 | (7.5M) | (7.86M) |
| Investing Cash Flow | (55K) | (199K) | (87.18M) | (106.1M) | 56.77M |
| Debt Repayment | (1.82M) | (8.68M) | 0 | 69.38M | 96.26M |
| Common Stock Issued | 169K | 570K | 6.9M | 3.02M | 5.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 198.84M | 0 | 0 | 2.66M |
| Financing Cash Flow | 53.16M | 190.73M | 6.9M | 72.4M | 104.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.54M | 150.46M | (139.55M) | (20.15M) | (9.5M) |
| Free Cash Flow | (17.62M) | (40.28M) | (59.44M) | 12.99M | (171.21M) |
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.